June 19, 2020 06:58 AM EDT

Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma

Amber Tong

When Epizyme scored the first-ever approval for tazemetostat, in epithelioid sarcoma, execs made it clear it was only an appetizer, something to whet the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Epizyme hits the ground run­ning with sec­ond — and cru­cial — OK for Tazverik, in fol­lic­u­lar lym­phoma

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma